Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

ABSTRACT Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This variable response among patients is in part due to genotype variability of CYP2C19, the gene encoding the CYP450 (CYP2C19) isoenzyme responsible for PPIs metabolism. Areas covered: This article provides an overview of the pharmacokinetics and mechanism of action of the currently available PPIs, including the magnitude of CYPC19 contribution to their metabolism. Additionally, the role of CYP2C19 genetic variability in the therapeutic effectiveness or outcomes of PPI therapy is highlighted in details, to provide supporting evidence for the potential value of CYP2C19 genotype-guided approaches to PPI drug therapy. Expert opinion: There is a large body of evidence describing the impact of CYP2C19 variability on PPIs and its potential role in individualizing PPI therapy, yet, CYP2C19 pharmacogenetics has not been widely implemented into clinical practice. More data are needed but CYP2C19 genotype-guided dosing of PPIs is likely to become increasingly common and is expected to improve clinical outcomes, and minimize side effects related to PPIs.

• Publication year

  2018

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2018-04-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17425255.2018.1461835PMID 29620484PMCID 5942154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux

  2018cited by this paper
• A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors

  2017cited by this paper
• Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment

  2017cited by this paper
• Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans

  2017cited by this paper
• Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?

  2016cited by this paper
• Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.

  2016cited by this paper
• Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

  2016cited by this paper
• Effect of proton pump inhibitors and antibiotics on the gut microbiome of hospitalised older persons.

  2016cited by this paper
• A comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors

  2016cited by this paper
• Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis

  2016cited by this paper
• Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis

  2016cited by this paper
• Adverse Effects Associated With Proton Pump Inhibitors.

  2016cited by this paper
• Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis

  2015cited by this paper
• Proton-pump inhibitors and risk of fractures: an update meta-analysis

  2015cited by this paper
• Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies

  2015influential reference
• Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.

  2015cited by this paper
• Table of Pharmacogenomic Biomarkers in Drug Labeling

  2015cited by this paper
• Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis

  2015cited by this paper
• First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.

  2015influential reference
• Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study.

  2015cited by this paper
• Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

  2015cited by this paper
• Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.

  2014cited by this paper
• Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese

  2014cited by this paper
• Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

  2014cited by this paper
• Clinical pharmacogenetics implementation: Approaches, successes, and challenges

  2014cited by this paper
• Twice‐daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice‐daily omeprazole, rabeprazole or lansoprazole

  2013cited by this paper
• Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors

  2013cited by this paper
• Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.

  2013cited by this paper
• Gastroesophageal Reflux: Management Guidance for the Pediatrician

  2013cited by this paper
• Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials

  2013cited by this paper
• What's Hot in the Red Journal This Month

  2013cited by this paper
• Proton Pump Inhibitors in Pediatrics

  2013cited by this paper
• Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine

  2013influential reference
• Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.

  2013cited by this paper
• Absorption, Distribution, Metabolism and Excretion of [14C]Dexlansoprazole in Healthy Male Subjects

  2012influential reference
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19

  2012cited by this paper
• Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array

  2012cited by this paper
• Pharmacogenomics Knowledge for Personalized Medicine

  2012influential reference
• Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection

  2012cited by this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cited by this paper
• Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.

  2012cited by this paper
• Poor effectiveness of proton pump inhibitors in non‐erosive reflux disease: the truth in the end!

  2012cited by this paper
• CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers

  2012influential reference
• Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis

  2012cited by this paper
• Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project

  2012cited by this paper
• A comparison of the acid‐inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2012cited by this paper
• The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics

  2012cited by this paper
• Adherence and dosing frequency of common medications for cardiovascular patients.

  2012cited by this paper
• Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics.

  2011influential reference
• Pharmacogenetics: From Bench to Byte— An Update of Guidelines

  2011influential reference
• Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood

  2011cited by this paper
• Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection

  2011cited by this paper
• 의사 간호사 communication

  2011cited by this paper
• CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

  2011influential reference
• Intragastric acidity during administration of generic omeprazole or esomeprazole – a randomised, two‐way crossover study including CYP2C19 genotyping

  2011cited by this paper
• Update on the pharmacogenomics of proton pump inhibitors.

  2011cited by this paper
• A Multicenter, Randomized, Open‐Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease

  2011cited by this paper
• Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)

  2010cited by this paper
• A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2010influential reference
• Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole

  2010cited by this paper
• Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.

  2009cited by this paper
• CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole

  2009influential reference
• Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.

  2009cited by this paper
• Rabeprazole

  2009cited by this paper
• Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

  2008influential reference
• Pharmacology of proton pump inhibitors

  2008cited by this paper
• Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor‐Based Triple Therapy for Helicobacter pylori Eradication: A Meta‐Analysis

  2008cited by this paper
• Pharmacogenetics: From Bench to Byte

  2008influential reference
• Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.

  2008influential reference
• Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

  2008influential reference
• Proton pump inhibitors: an update of their clinical use and pharmacokinetics

  2008cited by this paper
• CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.

  2007cited by this paper
• Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics.

  2007influential reference
• Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

  2007cited by this paper
• Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients

  2006cited by this paper
• Review article: acid‐related disease – what are the unmet clinical needs?

  2006cited by this paper
• Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism

  2006influential reference
• Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype

  2006cited by this paper
• Review article: the clinical pharmacology of proton pump inhibitors

  2006cited by this paper
• A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

  2006cited by this paper
• Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

  2006cited by this paper
• Esomeprazole‐induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: Evidence from clinical and pharmacokinetic data

  2005influential reference
• CYP2C19 genotype and the PPIs – focus on rabeprazole

  2005cited by this paper
• Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects

  2005cited by this paper
• CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole‐based quadruple therapy for eradication of Helicobacter Pylori

  2004cited by this paper
• Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

  2004cited by this paper
• Review article: pH, healing and symptom relief with rabeprazole treatment in acid‐related disorders

  2004cited by this paper
• Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole

  2004cited by this paper
• Esomeprazole 40 mg Provides Improved Intragastric Acid Control as Compared with Lansoprazole 30 mg and Rabeprazole 20 mg in Healthy Volunteers

  2004cited by this paper
• The Use of Proton Pump Inhibitors in Children

  2003cited by this paper
• Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease

  2003influential reference
• Proton Pump Inhibitors in Pediatrics: Relevant Pharmacokinetics and Pharmacodynamics

  2003cited by this paper
• Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

  2003influential reference
• The Clinical Importance of Proton Pump Inhibitor Pharmacokinetics

  2002cited by this paper
• Effect of high‐dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19

  2001influential reference
• Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

  2001cited by this paper
• Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole

  2001cited by this paper
• Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole

  2001cited by this paper
• Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH

  2001cited by this paper
• Proton pump inhibitors: better acid suppression when taken before a meal than without a meal

  2000cited by this paper

• Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study.

  2026cites this paper
• Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency.

  2026cites this paper
• CYP2C19 genetic polymorphisms and proton pump inhibitor therapy resistance in patients with gastrooesophageal reflux disease: a preliminary observational cohort study

  2026cites this paper
• Precision gastroenterology in pediatrics: CYP2C19 and individual metabolism of proton pump inhibitors in children with autism spectrum disorder

  2026cites this paper
• Gene, genetics and genetic medicines in gastroenterology: Current status and its future

  2026cites this paper
• CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use

  2026cites this paper
• Still a dilemma! Are vonoprazan and esomeprazole attenuating the antiplatelet function of clopidogrel when taken concomitantly? A systematic review and meta-analysis

  2025cites this paper
• Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review

  2025influential citation
• Mortality Risk Analysis of Combination Antiplatelet Therapy in Patients with Ischemic Stroke and Acute Kidney Injury: A Retrospective Cohort Analysis of the MIMIC-IV Database

  2025cites this paper
• Comorbid patient with gastroesophageal reflux disease: Features of the choice of proton pump inhibitor

  2025cites this paper
• Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach

  2025cites this paper
• Investigating low molecular weight phenolics for inhibition of H+/K+-ATPase activity: Insights from in vivo and in silico approaches

  2025cites this paper
• Role of the CYP450 Enzymatic Pathway in Drug Metabolism: Focus on Proton-pump Inhibitors and Antiplatelet Therapy

  2025cites this paper
• Rutin-loaded raft-forming systems developed from alginate and whey protein isolate for the treatment of gastric ulcers

  2025cites this paper
• Advances in Peptic Ulcer Treatment: Role of Vonoprazan, Tegoprazan, Keverprazan, and Anaprazole

  2025cites this paper
• CYP2C19 variability and clinical outcomes of clopidogrel, proton pump inhibitors, and voriconazole in Southeast Asia: a systematic review and meta-analysis

  2025cites this paper
• Effect of Acupuncture on Pneumonia Risk in Stroke Patients using Proton Pump Inhibitors: A Retrospective Case‐Control Study

  2025cites this paper
• An Outline on benzimidazole Containing Marketed Drugs with Proton Pump Inhibitor and H1 Receptor Antagonist Activities.

  2025cites this paper
• High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism among Patients with Gastroesophageal Reflux Disease.

  2025cites this paper
• Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Meta‐Analysis of Noninferiority Randomized Controlled Trials

  2025cites this paper
• Comparative Analysis of the Efficacy of Esomeprazole and Ilaprazole in Patients With Neurological Disorders Using the Gastroesophageal Reflux Disease Questionnaire

  2025cites this paper
• Successful treatment of refractory gastroesophageal reflux-induced chronic cough with vonoprazan: a report of three cases.

  2025cites this paper
• Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker– and Proton Pump Inhibitor–Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Network Meta-Analysis

  2025cites this paper
• Updates in Gastroesophageal Reflux Disease Management: From Proton Pump Inhibitors to Dietary and Lifestyle Modifications

  2025cites this paper
• Proton pump inhibitors and the risk of Clostridioides difficile infection: A systematic review and dose-response meta-analysis.

  2025cites this paper
• Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis

  2025cites this paper
• The effect of the genetic polymorphism of CYP2C19 on the effectiveness of eradication of Helicobacter pylori infection, a key factor in gastric carcinogenesis

  2025cites this paper
• Allele and genotype frequencies of variants in P450 cytochromes, transports, and DNA repair enzymes in the Dominican Republic population

  2025cites this paper
• Optimizing proton-pump inhibitor therapy in paediatric eosinophilic esophagitis through CYP2C19 pharmacogenetic testing

  2025cites this paper
• In Vitro Anti-Inflammatory and Anti-Ulcerogenic Potential of Ethanol Extract of Carica papaya Leaves: Phytochemical and Molecular Docking Studies

  2025cites this paper
• Successful Treatment of Refractory Helicobacter pylori Infection with a Potassium-Competitive Acid Blocker-Based Regimen: A Case Report.

  2025cites this paper
• Recomendaciones de buena práctica clínica en la prescripción y deprescripción de inhibidores de la bomba de protones. Revisión por expertos de la AMG

  2025cites this paper
• The ratio of omega-6 fatty acids to omega-3 fatty acids mediating the effect of gastroesophageal reflux disease on pancreatic cancer risk: a two-step mediation Mendelian randomisation study

  2025cites this paper
• Comparative Efficacy of Potassium-Competitive Acid Blockers (P-CABs) Versus Proton Pump Inhibitors (PPIs) in the Management of Erosive Esophagitis: A Systematic Review

  2025cites this paper
• Association of Physicians of India Consensus Recommendations for Vonoprazan in Management of Acid Peptic Disorders.

  2025cites this paper
• Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System

  2025cites this paper
• The influence of genetic polymorphism of the CYP2C19 gene on the results of eradication therapy for Helicobacter pylori infection

  2025cites this paper
• In-silico Assessment of CYP2C19 and CYP3A4 Inhibitory Potential of Ilaprazole

  2025cites this paper
• Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach

  2025cites this paper
• Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker

  2025cites this paper
• Fracture Risk Linked to Proton Pump Inhibitors Versus H2 Receptor Antagonists in Autoimmune Rheumatic and Gastrointestinal Disease Patients

  2025cites this paper
• TARGETED DRUG DELIVERY THROUGH CRISPR‒CAS9: BRIDGING BIOPHARMACEUTICS AND PHARMACOKINETICS

  2025cites this paper
• Association between CYP2C19 gene polymorphisms and Helicobacter pylori infection in Hainan region

  2025cites this paper
• The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis.

  2025cites this paper
• Comparative Efficacy of Vonoprazan and Proton Pump Inhibitors in Gastrointestinal Ulcer Healing and Post-ESD Bleeding Prevention

  2025cites this paper
• Potassium-competitive acid blockers.

  2025cites this paper
• Pharmaceutical and clinical implications of proton pump inhibitors with dual antiplatelet therapies: a systematic review

  2025cites this paper
• Good clinical practice recommendations for proton pump inhibitor prescription and deprescription. A review by experts from the AMG.

  2025cites this paper
• Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors

  2025influential citation
• Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection

  2024cites this paper
• A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing

  2024cites this paper
• Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour

  2024cites this paper
• Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam

  2024cites this paper
• Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians

  2024cites this paper
• A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients

  2024cites this paper
• Computational drug–drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel

  2024cites this paper
• RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis

  2024cites this paper
• An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?

  2024cites this paper
• Helicobacter pylori antibiotic resistance profile in Chinese children with upper gastrointestinal symptoms and a literature review for developing personalized eradicating strategies

  2024cites this paper
• Evaluation of Obesity‐Related Physiological Changes on Pantoprazole Clearance in Children Using a Population Pharmacokinetic Approach

  2024cites this paper
• P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis

  2024cites this paper
• Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024

  2024cites this paper
• Role of Proton Pump Inhibitors in Cardiac Patients: Guideline Recommendations Versus Practical Approach

  2024cites this paper
• POPULATION PHARMACOKINETICS OF PANTOPRAZOLE IN PATIENTS ON DUAL ANTIPLATELET THERAPY FOLLOWING ACUTE CORONARY SYNDROME

  2024cites this paper
• Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children

  2024cites this paper
• Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review.

  2024cites this paper
• Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología.

  2024cites this paper
• Mitigating digestive disorders: Action mechanisms of Mediterranean herbal active compounds

  2024cites this paper
• Effects of the EM CYP2C19 type and MDR1 3435CC gene on Helicobacter pylori eradication rate in patients with duodenal ulcer by the four-drug regimen of rabeprazole, bismuth, tetracycline, and tinidazole

  2024cites this paper
• Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics

  2024cites this paper
• Refractory Gastroesophageal Reflux Disease: Diagnosis and Management

  2024cites this paper
• Relationship between CYP2C19 genotypes and proton pump inhibitorsʹs pharmacokinetics and pharmacodynamics: review

  2024cites this paper
• When to use proton pump inhibitors

  2024cites this paper
• PROTON PUMP INHIBITORS: PROLONGED INTAKE AND ADVERSE EFFECTS.

  2024cites this paper
• Widening spectrum of adverse effects caused by long-term use of proton pump inhibitors: A comprehensive review of literature

  2024cites this paper
• A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran.

  2024cites this paper
• Pharmacological and Biological Relevance in the Medical Treatment of Laryngopharyngeal Reflux: A State-of-the-Art Review.

  2024cites this paper
• Association Between Clinical Use of Lansoprazole and the Risk of Coronary Heart Disease: A Nationwide Pharmacoepidemiological Cohort Study

  2024cites this paper
• Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities.

  2024cites this paper
• A study on appropriate use and stewardship of proton pump inhibitors

  2024cites this paper
• Challenging the efficacy and safety of clopidogrel versus aspirin monotherapy in secondary prevention of coronary artery disease: a comprehensive review

  2024cites this paper
• Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico. Revisión por expertos de la Asociación Mexicana de Gastroenterología

  2024cites this paper
• The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy

  2024cites this paper
• A Thermal-Analysis-Technique-Based Mechanistic Approach toward the Release of Omeprazole from Solid Dosage Forms

  2024influential citation
• Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease

  2024cites this paper
• From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice

  2024cites this paper
• Relationships of Proton Pump Inhibitor‐Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study

  2024influential citation
• Accelerated risk of renal disease progression in pre-ESRD patients with proton pump inhibitors use: a nationwide population-based study

  2024cites this paper
• Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori

  2024influential citation
• Combined contributions of cytochrome P450s (CYPs) and non-enzymatic metabolism in the in vitro biotransformation of anaprazole, a novel proton pump inhibitor

  2023cites this paper
• Impact of Pharmacogenomics in Clinical Practice

  2023cites this paper
• What is the Current Clinical Impact of the CYP2CTG Haplotype?

  2023cites this paper
• A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens

  2023cites this paper
• Cardiovascular Compatibility of Proton Pump Inhibitors: Practice Recommendations

  2023cites this paper
• Using single cell atlas data to reconstruct regulatory networks

  2023cites this paper
• Proton pump inhibitors in pediatric practice

  2023cites this paper
• Association Study of Esomeprazole Pharmacokinetics and CYP2C19 Gene Polymorphisms

  2023cites this paper
• Drug-microbiota interactions: an emerging priority for precision medicine

  2023cites this paper
• Vietnam Association of Gastroenterology (VNAGE) consensus on the management of Helicobacter pylori infection

  2023cites this paper
• Prediction of gastric pH‐mediated drug exposure using physiologically‐based pharmacokinetic modeling: A case study of itraconazole

  2023cites this paper